BellaSeno Receives RegMedNet Award for Cultivating Excellence
Leipzig, Germany, December 06, 2018 - BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology, today announced it was awarded the 2018 Award for Cultivating Excellence by RegMedNet for its innovation, creativity, professionalism and investment in young professionals. BellaSeno won the public vote after five finalists were shortlisted by an expert jury. The award was established in 2017 to increase the visibility of the most valuable players in regenerative medicine.
BellaSeno was founded in 2015 by a group of seasoned regenerative medicine and medtech specialists and is located on Leipzig’s BioCity campus. To date, the Company has raised EUR 3.2 million in public grants and private equity, e.g. from Herbert Stadler, one of Germany’s top bioentrepreneurs, the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE).
The Company is developing novel, non-silicone-based breast implants from a biocompatible and absorbable polymer that is FDA-approved and CE-marked for a variety of other clinical applications. Multiple preclinical studies have shown that the implants are slowly absorbed by the body. During the process, the implant guides the growth of natural tissue from lipoaspirate, which is derived from the patient's own body via a routine liposuction procedure. After the implant has been fully absorbed, the result is a natural tissue with no foreign body remnants. BellaSeno’s implants are produced via additive manufacturing (AM), more commonly known as 3D-printing.
„As a young company in the implant and regenerative medicine field, we feel honored by the award,“ said Dr. Simon Champ, CEO of BellaSeno. „We are a diverse team of young engineers and biologists from around the world. Our goal is to advance additive manufacturing towards the development of new, flexible, absorbable breast implants.“
BellaSeno’s first product, Senella®, is a patented, porous, absorbable implant which will provide a step change in the quality of life of breast reconstruction and augmentation patients around the world. The Company believes it has the potential to disrupt the current breast reconstruction and augmentation markets, which at present are dominated by silicone implants. Comprehensive clinical trials are planned to commence in 2019.
RegMedNet is a community site that unites the diverse regenerative medicine community. The award comes with a month-long special feature on RegMedNet, featuring interviews with lab members and selected published research. BellaSeno will also receive a one year-long subscription to a Future Science Group title of their choice, and 50% off open access fees for up to five articles published in the peer-reviewed journal Regenerative Medicine.
BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig, Germany. The Company is developing novel absorbable breast implants made by additive manufacturing (3D-printing). The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB) and the European Fund for Regional Development (EFRE). The company is thereby co-funded from tax resources based on the budget adopted by the members of Saxon State Parliament.
Senella® is a patented porous implant made of absorbable Polycaprolactone (PCL) containing highly-specialised topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant absorbs over a span of two years and provides a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural breast – without remnants of foreign material and thus alleviates the complications found in current breast reconstruction and augmentation approaches.
Dr. Simon Champ
Deutscher Platz 5a (BioCity)
Tel.: +49 176 8033 7273
Dr. Ludger Wess / Ines-Regina Buth
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BellaSeno Receives RegMedNet Award for Cultivating Excellence here
News-ID: 1421535 • Views: 339
More Releases from BellaSeno GmbH
BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regener …
- Collaboration with Fraunhofer IZI further expanded - Funding provided by Sächsische Aufbaubank Leipzig, Germany, July 1, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in close collaboration with Fraunhofer Institute for Cell Therapy and Immunology
BellaSeno Wins Prestigious German Innovation Award 2021
- Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies Leipzig, Germany, May 18, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business - Medical Technologies. BellaSeno has been chosen among
BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facil …
- Seamless transition from R&D to commercial-scale additive manufacturing - Leading-edge cleanroom, no-touch manufacturing - GMP capabilities for internal and contract manufacturing Leipzig, Germany, November 17, 2020 - BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany. It is the one
BellaSeno and Charite - Universitaetsmedizin Berlin Collaborate Under BMBF-Funde …
- Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes - BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485 Leipzig, Germany, March 24, 2020 - BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charite - Universitaetsmedizin Berlin under the recently established SyMBoD consortium. Under the agreement, BellaSeno will design and manufacture personalized, 3D-printed, absorbable